KR100303681B1 - 수용성펩티드의서방성제제 - Google Patents

수용성펩티드의서방성제제 Download PDF

Info

Publication number
KR100303681B1
KR100303681B1 KR1019900010224A KR900010224A KR100303681B1 KR 100303681 B1 KR100303681 B1 KR 100303681B1 KR 1019900010224 A KR1019900010224 A KR 1019900010224A KR 900010224 A KR900010224 A KR 900010224A KR 100303681 B1 KR100303681 B1 KR 100303681B1
Authority
KR
South Korea
Prior art keywords
polymer
octreotide
peptide
somatostatin
glycolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019900010224A
Other languages
English (en)
Korean (ko)
Other versions
KR910002430A (ko
Inventor
데이비드보드머
존슨윙퐁
토마스키셀
호킨스발리얀드마울딩
오스카나겔르
제인에드나피어슨
Original Assignee
더블류. 하링, 지. 보이롤
노바티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더블류. 하링, 지. 보이롤, 노바티스 아게 filed Critical 더블류. 하링, 지. 보이롤
Publication of KR910002430A publication Critical patent/KR910002430A/ko
Application granted granted Critical
Publication of KR100303681B1 publication Critical patent/KR100303681B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019900010224A 1989-07-07 1990-07-06 수용성펩티드의서방성제제 Expired - Lifetime KR100303681B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22
US411347 1989-09-22
US377023 1995-01-20

Publications (2)

Publication Number Publication Date
KR910002430A KR910002430A (ko) 1991-02-25
KR100303681B1 true KR100303681B1 (ko) 2002-05-16

Family

ID=27007654

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019900010224A Expired - Lifetime KR100303681B1 (ko) 1989-07-07 1990-07-06 수용성펩티드의서방성제제
KR1019990039209A Expired - Lifetime KR100442931B1 (ko) 1989-07-07 1999-09-14 수용성 펩티드의 서방성 제제 및 그의 제조방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019990039209A Expired - Lifetime KR100442931B1 (ko) 1989-07-07 1999-09-14 수용성 펩티드의 서방성 제제 및 그의 제조방법

Country Status (27)

Country Link
JP (5) JPH0832624B2 (enrdf_load_stackoverflow)
KR (2) KR100303681B1 (enrdf_load_stackoverflow)
AT (1) AT406225B (enrdf_load_stackoverflow)
AU (2) AU641407B2 (enrdf_load_stackoverflow)
BE (1) BE1004486A3 (enrdf_load_stackoverflow)
CA (1) CA2020477C (enrdf_load_stackoverflow)
CH (1) CH685230A5 (enrdf_load_stackoverflow)
CY (1) CY1965A (enrdf_load_stackoverflow)
DE (2) DE4021517B4 (enrdf_load_stackoverflow)
DK (1) DK175849B1 (enrdf_load_stackoverflow)
FI (3) FI108611B (enrdf_load_stackoverflow)
FR (1) FR2649319A1 (enrdf_load_stackoverflow)
GB (2) GB2234896B (enrdf_load_stackoverflow)
GR (1) GR1001121B (enrdf_load_stackoverflow)
HK (2) HK97695A (enrdf_load_stackoverflow)
HU (2) HU221294B1 (enrdf_load_stackoverflow)
IE (2) IE64411B1 (enrdf_load_stackoverflow)
IL (3) IL131881A (enrdf_load_stackoverflow)
IT (1) IT1241460B (enrdf_load_stackoverflow)
LU (1) LU87764A1 (enrdf_load_stackoverflow)
MY (1) MY106722A (enrdf_load_stackoverflow)
NL (1) NL195027C (enrdf_load_stackoverflow)
NO (2) NO302928B1 (enrdf_load_stackoverflow)
NZ (1) NZ234384A (enrdf_load_stackoverflow)
PT (1) PT94628B (enrdf_load_stackoverflow)
SE (1) SE512992C2 (enrdf_load_stackoverflow)
SG (1) SG26416G (enrdf_load_stackoverflow)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
CA2123144A1 (en) * 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
HU219487B (hu) 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
AU717113B2 (en) 1995-11-09 2000-03-16 Health Protection Agency Microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
ATE361057T1 (de) 2000-12-21 2007-05-15 Alrise Biosystems Gmbh Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
US20070259047A1 (en) * 2004-02-26 2007-11-08 Yasuaki Ogawa Protein Sustained-Release Microparticle Preparation for Injection and Process for Producing the Same
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
BRPI0620063B8 (pt) * 2005-12-22 2021-05-25 Novartis Ag composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
ES2522342T3 (es) 2008-01-30 2014-11-14 Novartis Ag Formulación de liberación sostenida que comprende octreótido y tres polímeros lineales de polilactida-co-glicolida
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2813302A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Emulsion method for preparing low residual solvent microparticles
CA2813301A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Method for removing residual organic solvent from microparticles
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
IL301455B2 (en) 2016-08-31 2024-04-01 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOSIT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH644768A5 (de) * 1977-08-25 1984-08-31 Sandoz Ag Verfahren zur herstellung von mikrokugeln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
DE3062075D1 (en) * 1979-11-27 1983-03-24 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (enrdf_load_stackoverflow) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
IL131880A (en) 2001-12-23
FI109543B (fi) 2002-08-30
NO983923L (no) 1991-01-08
NL9001537A (nl) 1991-02-01
DE4042752B4 (de) 2009-05-07
GB2265311A (en) 1993-09-29
JP2931773B2 (ja) 1999-08-09
IE64411B1 (en) 1995-08-09
SE9002364L (sv) 1991-01-08
GR900100513A (en) 1991-12-10
AU641407B2 (en) 1993-09-23
MY106722A (en) 1995-07-31
IT1241460B (it) 1994-01-17
FI109334B (fi) 2002-07-15
HK197496A (en) 1996-11-08
CH685230A5 (de) 1995-05-15
JP2001233897A (ja) 2001-08-28
HUT54037A (en) 1991-01-28
GB9014704D0 (en) 1990-08-22
SG26416G (en) 1995-09-01
PT94628A (pt) 1991-03-20
JPH07285853A (ja) 1995-10-31
FR2649319A1 (fr) 1991-01-11
JPH0832624B2 (ja) 1996-03-29
IL131881A (en) 2001-12-23
FI20000060L (fi) 2000-01-12
GB2265311B (en) 1994-02-09
SE9002364D0 (sv) 1990-07-05
NL195027C (nl) 2003-12-02
DE4021517A1 (de) 1991-01-17
NL195027B (nl) 2003-08-01
CA2020477C (en) 2000-11-21
NO983923D0 (no) 1998-08-26
GB2234896A (en) 1991-02-20
DK175849B1 (da) 2005-03-29
IE902435A1 (en) 1991-02-13
GB2234896B (en) 1994-01-19
NO320444B1 (no) 2005-12-05
JPH0368511A (ja) 1991-03-25
JPH07309897A (ja) 1995-11-28
IE64216B1 (en) 1995-07-26
NZ234384A (en) 1994-05-26
AU687553B2 (en) 1998-02-26
SE512992C2 (sv) 2000-06-12
AT406225B (de) 2000-03-27
FR2649319B1 (enrdf_load_stackoverflow) 1994-12-09
DK162590A (da) 1991-01-08
NO903001D0 (no) 1990-07-05
IL94983A0 (en) 1991-06-10
GR1001121B (el) 1993-04-28
KR910002430A (ko) 1991-02-25
AU5874690A (en) 1991-01-10
NO302928B1 (no) 1998-05-11
JPH08198771A (ja) 1996-08-06
IT9048113A0 (it) 1990-07-05
CA2020477A1 (en) 1991-01-08
AU2332195A (en) 1995-09-07
ATA144090A (de) 1999-08-15
CY1965A (en) 1997-07-04
NO903001L (no) 1991-01-08
PT94628B (pt) 1997-06-30
DE4021517B4 (de) 2009-04-09
HU221294B1 (en) 2002-09-28
LU87764A1 (fr) 1992-03-11
FI20000059L (fi) 2000-01-12
HU903974D0 (en) 1990-11-28
HU211602A9 (en) 1995-12-28
DK162590D0 (da) 1990-07-05
FI108611B (fi) 2002-02-28
IT9048113A1 (it) 1992-01-05
IL94983A (en) 1999-08-17
HK97695A (en) 1995-06-23
KR100442931B1 (ko) 2004-08-02
BE1004486A3 (fr) 1992-12-01
FI903429A0 (fi) 1990-07-06
GB9306204D0 (en) 1993-05-19

Similar Documents

Publication Publication Date Title
KR100303681B1 (ko) 수용성펩티드의서방성제제
US5876761A (en) Sustained release formulations of water soluble peptides
US5688530A (en) Sustained release formulations of water soluble peptides
JP4979843B2 (ja) 微粒子の形のポリペプチド含有投薬形
KR19990067014A (ko) 용융 공정에 의해 펩티드를 포함하는 생분해가능한미소구의 제조
CA2316052C (en) Sustained release formulations of water soluble peptides
JPH08225454A (ja) マイクロスフェア製剤
CA2535463A1 (en) Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
NL195090C (nl) Preparaten van in water oplosbare peptiden met een langzame afgifte.
CY1844A (en) Sustained release formulations of water soluble peptides
IL112286A (en) Process for the production of a microparticle and microparticle obtained thereby
FI106926B (fi) Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900706

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950706

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900706

Comment text: Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19980227

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980410

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19981010

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 19990113

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 19981010

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20010228

Appeal identifier: 1999101000181

Request date: 19990113

A107 Divisional application of patent
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 19990212

Patent event code: PA01071R01D

PB0901 Examination by re-examination before a trial

Comment text: Request for Trial against Decision on Refusal

Patent event date: 19990113

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19980910

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19950706

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19990113

Effective date: 20010228

Free format text: TRIAL NUMBER: 1999101000181; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19990113

Effective date: 20010228

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20010308

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 19990113

Decision date: 20010228

Appeal identifier: 1999101000181

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20010412

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20010312

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20010712

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20010713

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20040609

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20050603

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20060623

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20070710

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20080701

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20090708

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20100712

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20110617

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20120620

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20120620

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20130620

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20130620

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20140701

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20140701

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20150618

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20150618

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term